A case study of personalized therapy for osteosarcoma. Issue 8 (22nd March 2013)

• Record Type: Journal Article
• Authors: Davis, Lara E.; Hofmann, Nicolle E.; Li, Guangheng; Huang, Elaine T.; Loriaux, Marc M.; Bracha, Shay; Helfand, Stuart C.; Mata, John E.; Marley, Kevin; Mansoor, Atiya; Tyner, Jeffrey W.; Abraham, Jinu; Séguin, Bernard; Keller, Charles
• Is Part Of: Pediatric blood & cancer. Volume 60:Issue 8(2013:Aug.)
• Page Start: 1313
• Page End: 1319
• Publication Date: 2013-03-22
• Subjects: Tumors in children -- Periodicals; Blood -- Diseases -- Periodicals; Cancer in children -- Periodicals; 618.92
• DOI: 10.1002/pbc.24512
• Languages: English
• ISSNs: 1545-5009

Abstract

<abstract abstract-type="main" xml:lang="en"> <title>Abstract</title> <sec id="pbc24512-sec-0001" sec-type="section"> <title>Background</title> <p>Effective targeted therapies are needed in sarcomas, but the biological heterogeneity of these tumors has presented a challenge to clinical integration of small molecule inhibitors in sarcoma treatment. Here we outline a process to personalize therapy for sarcomas through a case study of a canine with spontaneous osteosarcoma.</p> </sec> <sec id="pbc24512-sec-0002" sec-type="section"> <title>Procedure</title> <p>Rapid establishment of a primary tumor cell culture is described, followed by efficient functional characterization of the tumor that identified the Src inhibitor dasatinib as the most effective targeted therapy for this individual dog.</p> </sec> <sec id="pbc24512-sec-0003" sec-type="section"> <title>Results</title> <p>Adjuvant dasatinib was administered for a total of 26 weeks following treatment with chemotherapy. Pharmacokinetic studies confirm that a therapeutic serum concentration was achieved at a tolerable dose of 0.75 mg/kg/day. The canine patient remains without evidence of recurrent disease 24 months following initial diagnosis.</p> </sec> <sec id="pbc24512-sec-0004" sec-type="section"> <title>Conclusions</title> <p>The approach described through this illustrative case study is broadly applicable and might be used for other solid tumors in canines as well as in humans. Pediatr Blood Cancer 2013;60:1313–1319. © 2013 Wiley Periodicals, Inc.</p> </sec> </abstract>